28 June 2024
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Result of AGM
Change of Name of Nominated Adviser and Joint Broker
Cambridge Cognition plc (AIM: COG), which develops and markets digital solutions to assess brain health, held its Annual General Meeting ("AGM") earlier today at the registered office of the Company; Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces that all resolutions put forward were duly passed.
Proxy votes were received in respect of approximately 55% of the Company's issued share capital and the votes cast were as follows:
| Resolution | For |
| Against |
| Withheld |
| 1 - to approve the 2023 report and accounts | 22,321,648 | 99.98% | 5,003 | 0.02% | 642,810 |
| 2 - to appoint the auditors | 22,930,519 | 99.96% | 8,503 | 0.04% | 30,439 |
| 3 - to authorise the directors to set the auditors remuneration | 22,942,198 | 99.98% | 5,003 | 0.02% | 22,260 |
| 4 - to re-elect Richard Bungay as a director | 20,756,611 | 98.92% | 226,842 | 1.08% | 1,986,008 |
| 5 - to elect Nick Rodgers as a director | 22,927,961 | 99.82% | 40,492 | 0.18% | 1,008 |
| 6 - to elect Stuart Gall as a director | 22,927,961 | 99.82% | 40,492 | 0.18% | 1,008 |
| 7 - authority to allot shares | 22,798,499 | 99.26% | 169,954 | 0.74% | 1,008 |
| 8 - disapplication of pre-emption rights | 22,789,981 | 99.22% | 178,472 | 0.78% | 1,008 |
| 9 - disapplication of pre-emption rights in connection with an acquisition or specified capital investment | 22,788,299 | 99.22% | 180,154 | 0.78% | 1,008 |
Change of Name of Nominated Adviser and Broker
The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.
Enquiries
| Tel: 01223 810 700
| |||
| Tel: 020 78862500 (Corporate Advisory) (Corporate Broking) | |||
| Tel: 020 3903 7715 (Corporate Broking) | |||
| Hudson Sandler (Financial PR and IR) Dan de Belder / Hattie Dreyfus | Tel: 020 7796 4133 |
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company marketing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
